Novartis AG
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $74.89B | $7.01B |
| FY2017 | — | $74.17B | $8.86B |
| FY2018 | — | $74.29B | $13.27B |
| FY2019 | — | $55.47B | $11.11B |
| FY2020 | — | $56.60B | $9.66B |
| FY2021 | — | $67.66B | $12.41B |
| FY2022 | — | $59.34B | $7.52B |
| FY2023 | — | $46.67B | $13.39B |
| FY2024 | — | $44.05B | $11.46B |
| FY2025 | — | $46.13B | $11.44B |